Alert: NIDA Funds Harvard Ibogaine OUD Research Towards IND Clearance

Harvard Medical School, supported by an $11M NIDA grant, is advancing ibogaine research for Opioid Use Disorder (OUD), aiming for Investigational New Drug (IND) clearance to conduct Phase I and II clinical trials in the U.S. This initiative is distinct from prior noribogaine trials, seeking to study ibogaine itself at higher doses. Securing IND clearance for ibogaine would be a significant milestone for the psychedelic therapeutics landscape.